Abstract Adopting the Quality by Design (QbD) approach in the drug development process
has transformed from “nice-to-do” into a crucial and required part of the development …

Introduction The development of long-acting injectables (LAIs) for protein and peptide
therapeutics has been a key challenge over the last 20 years. If these molecules offer …

Limited drug solubility effects can play a major role for the control of drug release from a
variety of drug delivery systems, eg tablets, pellets, implants and microparticles. Importantly …

A transdermal delivery approach may circumvent the limitations associated with the oral use
of risperidone (RIS), an atypical antipsychotic drug. The current study focuses on the …

Stimuli-sensitive Pluronic®-based pentablock copolymers (PBCs), which are reversible
polymer networks created by physical interactions, exhibit a sol–gel phase transition in …

Sandostatin long-acting release®(SLAR) is a long-acting injectable somatostatin analogue
formulation composed of octreotide encapsulated in glucose-initiated poly (lactic-co-glycolic …

Long-acting injectable microspheres have been on the market for more than three decades,
but if calculated on the brand name, only 12 products have been approved by the FDA due …

Releasing a protein according to a zero-order profile without protein denaturation during the
polymeric microparticle degradation process is very challenging. The aim of the current …

A novel polyimide-inlaid amine-rich porous organic block copolymer (PI-b-ARPOP) was
prepared via one-step polymerization by using different molar ratios of melamine (MA) …

In order to improve the sustained release properties of carriers and explore the effect of
copolymer sequence structures on sustained release, 5 groups of 12 block copolymers (12 …